soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm SOUL: Oral Semaglutide Bests Usual Care in SOUL trial shows oral semaglutide

Cardiovascular outcome trials (including LEADER, SUSTAIN-6, REWIND, and SELECT) have demonstrated that certain GLP-1 receptor agonists reduce major adverse cardiovascular events in patients with established cardiovascular disease or multiple risk factors

Because IV therapy lacks FDA approval for skin lightening, and the long-term effects remain unknown, it is crucial to weigh the effectiveness against these potential side effects

Having sufficient knowledge of the GSH system and the regulation and functions of GPx is essential to prevent metabolic alterations and to develop effective strategies for treating these diseases

Weight loss injections like semaglutide can restore hormonal balance, improve insulin sensitivity, and make ovulation more regular, which may increase fertility